Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Innovative approach to an Individualised T-Cell Immunotherapy for cancer, using Personalised Tumour Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implement

Project description

Training lymphocytes to recognise tumour-specific antigens

Cancer treatment remains a significant medical challenge due to the diverse mutations and generated neoantigens in each tumour. As a result, immunotherapy has met limited clinical success. Funded by the European Innovation Council, the NEOpTTL project proposes a new approach – producing personalised tumour-trained lymphocytes (pTTL) harvested from regional lymph nodes. The method employs proprietary technologies such as machine learning to predict the most effective neoantigens in the tumour. The idea is that upon reinfusion into the patient, these pTTLs will identify tumour neoantigens and kill cancer cells. The therapy will be tested in patients with advanced colorectal cancer in a phase I/II clinical trial during the project.

Objective

NEOGAP has developed a groundbreaking personalised adoptive T cell therapy for treating solid tumours based on two proprietary technologies: PIOR® machine learning software and EpiTCer®. This cancer immunotherapy consists of producing personalised Tumour Trained Lymphocytes (pTTL), which are autologous T-cells harvested from regional lymph nodes, subjected to a neoantigen-driven T-cell stimulation technology to deliver highly tumour-reactive T-cell clones (pTTLs). pTTLs are re-infused to the patient where they infiltrate and kill cancer cells, leaving healthy cells untouched. The therapy is broadly applicable to many cancer types, being personalised to each individual patient. In this EIC accelerator project, NEOGAP plans to complete the Phase 1b part of the first in human clinical trial of the therapy in advanced colorectal cancer patients, focused on safety assessment and biomarker exploration and optimise the manufacturing process for the next clinical studies.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

NEOGAP THERAPEUTICS AB
Net EU contribution
€ 2 500 000,00
Address
CENTER FOR MOLECULAR MEDICINE KAROLINSKA SJUKHUSET L8 02
171 76 STOCKHOLM
Sweden
SME
Yes
Region
Östra Sverige Stockholm Stockholms län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 8 422 865,06